Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts
NCT ID: NCT05291845
Last Updated: 2025-06-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
162 participants
INTERVENTIONAL
2022-04-03
2025-12-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intralesional Versus Intramuscular Hepatitis B Vaccine Immunotherapy for Warts
NCT05326152
Sclerotherapy and Candida Antigen in Treatment of Common Warts
NCT06749665
Gardasil Versus Cervarix in the Treatment of Warts
NCT05383625
Comparison Between Intralesional Injection of Plasma Rich Platelets and Candida Antigen in Plane Warts
NCT05652998
Intralesional Candidal Antigen Versus Intralesional Zinc Sulphate in Treatment of Cutaneous Warts
NCT03158168
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Group B: 54 patients will be treated with bivalent HPV vaccine solution intralesional into the largest wart using an insulin syringe. Injections will be done at 2-week intervals until complete clearance will be achieved or for a maximum of five treatment sessions.
* Group C: 54 patients will be treated with both agents intralesionally into the largest wart using an insulin syringe at 2-week intervals until complete clearance will be achieved or for a maximum of five treatment sessions.
it is thought that candida antigen act through a cell-mediated immune response and bivalent HPV vaccine act mainly through humoral immunity, so we want to study their effect as single or mixed agents
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Candida antigen group
54 patients will be treated with Candida antigen. All patients will be directly injected with Candida antigen into the largest wart using an insulin syringe. Injections will be done at 2-week intervals until complete clearance will be achieved or for a maximum of five treatment sessions.
Candida antigen vaccine
we will study the efficacy and safety of agent in the treatment of multiple warts, we will follow up the recurrence rate of each group
Bivalent HPV vaccine
54 patients will be treated with the Bivalent HPV vaccine. All patients will be directly injected with the vaccine into the largest wart using an insulin syringe. Injections will be done at 2-week intervals until complete clearance will be achieved or for a maximum of five treatment sessions.
Bivalent HPV vaccine
we will study the efficacy and safety of agent in the treatment of multiple warts, we will follow up the recurrence rate of each group
both agents group
54 patients will be treated with Both agents at the same session. Injections will be done at 2-week intervals until complete clearance will be achieved or for a maximum of five treatment sessions.
Candida antigen vaccine
we will study the efficacy and safety of agent in the treatment of multiple warts, we will follow up the recurrence rate of each group
Bivalent HPV vaccine
we will study the efficacy and safety of agent in the treatment of multiple warts, we will follow up the recurrence rate of each group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Candida antigen vaccine
we will study the efficacy and safety of agent in the treatment of multiple warts, we will follow up the recurrence rate of each group
Bivalent HPV vaccine
we will study the efficacy and safety of agent in the treatment of multiple warts, we will follow up the recurrence rate of each group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
9 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zagazig University
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Reham Essam
Lecturer of Dermatology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Reham Essam, MD
Role: PRINCIPAL_INVESTIGATOR
Zagazig University
Ahmad Nofal, MD
Role: STUDY_DIRECTOR
Zagazig University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Reham Essam
Zagazig, Al Sharqia, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Nofal A, Marei A, Ibrahim AM, Nofal E, Nabil M. Intralesional versus intramuscular bivalent human papillomavirus vaccine in the treatment of recalcitrant common warts. J Am Acad Dermatol. 2020 Jan;82(1):94-100. doi: 10.1016/j.jaad.2019.07.070. Epub 2019 Jul 29.
Nassar A, Alakad R, Essam R, Bakr NM, Nofal A. Comparative efficacy of intralesional Candida antigen, intralesional bivalent human papilloma virus vaccine, and cryotherapy in the treatment of common warts. J Am Acad Dermatol. 2022 Aug;87(2):419-421. doi: 10.1016/j.jaad.2021.08.040. Epub 2021 Aug 28. No abstract available.
Related Links
Access external resources that provide additional context or updates about the study.
Intralesional versus intramuscular bivalent human papillomavirus vaccine in the treatment of recalcitrant common warts
Comparative efficacy of intralesional Candida antigen, intralesional bivalent human papilloma virus vaccine, and cryotherapy in the treatment of common warts
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C.ag-vs-B.HPV.V
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.